Cargando…

Decreased PCSK9 expression in human hepatocellular carcinoma

BACKGROUND: The management of hepatocellular carcinoma (HCC) is limited by the lack of adequate screening biomarkers and chemotherapy. In response, there has been much interest in tumor metabolism as a therapeutic target. PCSK9 stimulates internalization of the LDL-receptor, decreases cholesterol up...

Descripción completa

Detalles Bibliográficos
Autores principales: Bhat, Mamatha, Skill, Nicolas, Marcus, Victoria, Deschenes, Marc, Tan, Xianming, Bouteaud, Jeanne, Negi, Sarita, Awan, Zuhier, Aikin, Reid, Kwan, Janet, Amre, Ramila, Tabaries, Sebastien, Hassanain, Mazen, Seidah, Nabil G., Maluccio, Mary, Siegel, Peter, Metrakos, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4682218/
https://www.ncbi.nlm.nih.gov/pubmed/26674961
http://dx.doi.org/10.1186/s12876-015-0371-6
_version_ 1782405858950381568
author Bhat, Mamatha
Skill, Nicolas
Marcus, Victoria
Deschenes, Marc
Tan, Xianming
Bouteaud, Jeanne
Negi, Sarita
Awan, Zuhier
Aikin, Reid
Kwan, Janet
Amre, Ramila
Tabaries, Sebastien
Hassanain, Mazen
Seidah, Nabil G.
Maluccio, Mary
Siegel, Peter
Metrakos, Peter
author_facet Bhat, Mamatha
Skill, Nicolas
Marcus, Victoria
Deschenes, Marc
Tan, Xianming
Bouteaud, Jeanne
Negi, Sarita
Awan, Zuhier
Aikin, Reid
Kwan, Janet
Amre, Ramila
Tabaries, Sebastien
Hassanain, Mazen
Seidah, Nabil G.
Maluccio, Mary
Siegel, Peter
Metrakos, Peter
author_sort Bhat, Mamatha
collection PubMed
description BACKGROUND: The management of hepatocellular carcinoma (HCC) is limited by the lack of adequate screening biomarkers and chemotherapy. In response, there has been much interest in tumor metabolism as a therapeutic target. PCSK9 stimulates internalization of the LDL-receptor, decreases cholesterol uptake into hepatocytes and affects liver regeneration. Thus, we investigated whether PCSK9 expression is altered in HCC, influencing its ability to harness cholesterol metabolism. METHODS: Thirty-nine patients undergoing partial hepatectomy or liver transplantation for HCC were consented for use of HCC tissue to construct a tissue microarray (TMA). The TMA was immunostained for PCSK9. Imagescope software was used to objectively determine staining, and assess for pathological and clinical correlations. PCSK9 and LDL receptor mRNA levels in flash-frozen HCC and adjacent liver tissue were determined by quantitative RT-PCR. Serum PCSK9 levels were determined by ELISA. RESULTS: By immunohistochemistry, there was significantly lower expression of PCSK9 in HCC as compared to adjacent cirrhosis (p-value < 0.0001, wilcoxon signed-rank test). Significantly greater staining of PCSK9 was present in cirrhosis compared to HCC (p value <0.0001), and positivity (percentage of positive cells) was significantly greater in cirrhosis compared to HCC (p-value < 0.0001). Conversely, significantly higher expression of LDL-R was present in HCC as compared to the adjacent cirrhosis (p-value < 0.0001). There was no significant correlation of PCSK9 staining with grade of tumor, but there were significant correlations between PCSK9 staining and stage of fibrosis, according to spearman correlation test. PCSK9 mRNA levels were relatively less abundant within HCC compared to adjacent liver tissue (p-value =0.08) and normal control tissue (p-value =0.02). In contrast, serum PCSK9 levels were significantly increased among patients with HCC compared to those with chronic liver disease without HCC (p-value =0.029). LDL receptor mRNA was consistantly greater in HCC when compared to normal control tissue (p-value = 0.06) and, in general, was significantly greater in HCC when compared to adjacent liver (p-value = 0.04). CONCLUSIONS: The decreased expression of PCSK9 and conversely increased LDL-R expression in HCC suggests that HCC modulates its local microenvironment to enable a constant energy supply. Larger-scale studies should be conducted to determine whether PCSK9 could be a therapeutic target for HCC.
format Online
Article
Text
id pubmed-4682218
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-46822182015-12-18 Decreased PCSK9 expression in human hepatocellular carcinoma Bhat, Mamatha Skill, Nicolas Marcus, Victoria Deschenes, Marc Tan, Xianming Bouteaud, Jeanne Negi, Sarita Awan, Zuhier Aikin, Reid Kwan, Janet Amre, Ramila Tabaries, Sebastien Hassanain, Mazen Seidah, Nabil G. Maluccio, Mary Siegel, Peter Metrakos, Peter BMC Gastroenterol Research Article BACKGROUND: The management of hepatocellular carcinoma (HCC) is limited by the lack of adequate screening biomarkers and chemotherapy. In response, there has been much interest in tumor metabolism as a therapeutic target. PCSK9 stimulates internalization of the LDL-receptor, decreases cholesterol uptake into hepatocytes and affects liver regeneration. Thus, we investigated whether PCSK9 expression is altered in HCC, influencing its ability to harness cholesterol metabolism. METHODS: Thirty-nine patients undergoing partial hepatectomy or liver transplantation for HCC were consented for use of HCC tissue to construct a tissue microarray (TMA). The TMA was immunostained for PCSK9. Imagescope software was used to objectively determine staining, and assess for pathological and clinical correlations. PCSK9 and LDL receptor mRNA levels in flash-frozen HCC and adjacent liver tissue were determined by quantitative RT-PCR. Serum PCSK9 levels were determined by ELISA. RESULTS: By immunohistochemistry, there was significantly lower expression of PCSK9 in HCC as compared to adjacent cirrhosis (p-value < 0.0001, wilcoxon signed-rank test). Significantly greater staining of PCSK9 was present in cirrhosis compared to HCC (p value <0.0001), and positivity (percentage of positive cells) was significantly greater in cirrhosis compared to HCC (p-value < 0.0001). Conversely, significantly higher expression of LDL-R was present in HCC as compared to the adjacent cirrhosis (p-value < 0.0001). There was no significant correlation of PCSK9 staining with grade of tumor, but there were significant correlations between PCSK9 staining and stage of fibrosis, according to spearman correlation test. PCSK9 mRNA levels were relatively less abundant within HCC compared to adjacent liver tissue (p-value =0.08) and normal control tissue (p-value =0.02). In contrast, serum PCSK9 levels were significantly increased among patients with HCC compared to those with chronic liver disease without HCC (p-value =0.029). LDL receptor mRNA was consistantly greater in HCC when compared to normal control tissue (p-value = 0.06) and, in general, was significantly greater in HCC when compared to adjacent liver (p-value = 0.04). CONCLUSIONS: The decreased expression of PCSK9 and conversely increased LDL-R expression in HCC suggests that HCC modulates its local microenvironment to enable a constant energy supply. Larger-scale studies should be conducted to determine whether PCSK9 could be a therapeutic target for HCC. BioMed Central 2015-12-16 /pmc/articles/PMC4682218/ /pubmed/26674961 http://dx.doi.org/10.1186/s12876-015-0371-6 Text en © Bhat et al. 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Bhat, Mamatha
Skill, Nicolas
Marcus, Victoria
Deschenes, Marc
Tan, Xianming
Bouteaud, Jeanne
Negi, Sarita
Awan, Zuhier
Aikin, Reid
Kwan, Janet
Amre, Ramila
Tabaries, Sebastien
Hassanain, Mazen
Seidah, Nabil G.
Maluccio, Mary
Siegel, Peter
Metrakos, Peter
Decreased PCSK9 expression in human hepatocellular carcinoma
title Decreased PCSK9 expression in human hepatocellular carcinoma
title_full Decreased PCSK9 expression in human hepatocellular carcinoma
title_fullStr Decreased PCSK9 expression in human hepatocellular carcinoma
title_full_unstemmed Decreased PCSK9 expression in human hepatocellular carcinoma
title_short Decreased PCSK9 expression in human hepatocellular carcinoma
title_sort decreased pcsk9 expression in human hepatocellular carcinoma
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4682218/
https://www.ncbi.nlm.nih.gov/pubmed/26674961
http://dx.doi.org/10.1186/s12876-015-0371-6
work_keys_str_mv AT bhatmamatha decreasedpcsk9expressioninhumanhepatocellularcarcinoma
AT skillnicolas decreasedpcsk9expressioninhumanhepatocellularcarcinoma
AT marcusvictoria decreasedpcsk9expressioninhumanhepatocellularcarcinoma
AT deschenesmarc decreasedpcsk9expressioninhumanhepatocellularcarcinoma
AT tanxianming decreasedpcsk9expressioninhumanhepatocellularcarcinoma
AT bouteaudjeanne decreasedpcsk9expressioninhumanhepatocellularcarcinoma
AT negisarita decreasedpcsk9expressioninhumanhepatocellularcarcinoma
AT awanzuhier decreasedpcsk9expressioninhumanhepatocellularcarcinoma
AT aikinreid decreasedpcsk9expressioninhumanhepatocellularcarcinoma
AT kwanjanet decreasedpcsk9expressioninhumanhepatocellularcarcinoma
AT amreramila decreasedpcsk9expressioninhumanhepatocellularcarcinoma
AT tabariessebastien decreasedpcsk9expressioninhumanhepatocellularcarcinoma
AT hassanainmazen decreasedpcsk9expressioninhumanhepatocellularcarcinoma
AT seidahnabilg decreasedpcsk9expressioninhumanhepatocellularcarcinoma
AT malucciomary decreasedpcsk9expressioninhumanhepatocellularcarcinoma
AT siegelpeter decreasedpcsk9expressioninhumanhepatocellularcarcinoma
AT metrakospeter decreasedpcsk9expressioninhumanhepatocellularcarcinoma